ascopubs.org5d
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...
ascopubs.org5d
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...
ascopubs.org5d
A survival prediction model for veterans with advanced bladder cancer (BC) treated with immune checkpoint inhibitors (ICI).
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer. PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting ...
ascopubs.org5d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org5d
Impact of prior primary care utilization on limiting racial disparities for prostate cancer diagnosis and mortality.
Ethnic disparities in clinical trials for FDA-approved drugs in prostate cancer: A post–COVID-19 era analysis (2020-2024). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
ascopubs.org5d
Evaluation of de novo oligometastatic prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset.
Outcomes for 177Lu-PSMA-617 with and without concurrent use of ARPIs in patients with mCRPC.
ascopubs.org5d
Checkpoint blockade as neoadjuvant strategy: A single-arm meta-analysis of dual PD-1/PD-L1 and CTLA-4 inhibition in urothelial cancer.
Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis. Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients ...
ascopubs.org5d
Real-world prevalence and outcomes of androgen receptor ligand-binding domain mutations in prostate cancer.
Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC). Evaluating the association between bone pain and radiologic progression-free survival (rPFS) ...
ascopubs.org2d
Management of relapsed stage I seminomatous germ cell tumor with retroperitoneal or pelvic only relapse.
Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: Should regional therapy be considered the preferred treatment approach?
ascopubs.org5d
Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer.
Impact of adding immunotherapy to chemotherapy for metastatic neuroendocrine bladder cancer in the National Cancer Database. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
ascopubs.org10d
Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
ascopubs.org5d
Analysis of gene expression signatures in prostate cancer prior to liver metastases.
Impact of homologous recombination repair alterations (HRRalt) on survival outcomes of patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Effects of emerin dysregulation on the ...